iPSC Drug Discovery Platform

What will you cure?

With a long heritage in both iPSC technology and genome engineering, ASC brings deep expertise to advance your iPSC drug discovery programs toward the clinic and beyond.

Whether you start with our powerful TARGATT™ plug-and-play iPSC platform, leverage our off-the-shelf hypoimmunogenic iPSC lines for faster allogeneic development, or bring your own cells, our experienced team will engineer and differentiate your iPSCs to rapidly generate the functional cell types needed for your discovery and efficacy studies.

And when your program is ready to move forward, ASC will seamlessly transition your project to GMP development, rebuilding and differentiating your cells in our cleanrooms to generate materials suitable for IND-enabling studies and clinical programs.

Get a snapshot of how we can enable your iPSC program

Off-the-shelf GMP and matching research iPSCs

• TARGATT™ Hypoimmunogenic hiPSCs
• TARGATT™ hiPSCs
• ActiCells™ hiPSCs

Our off-the-shelf iPSCs are reprogrammed from CD34⁺ cord blood cells (male)

Genome engineering technologies

• TARGATT™ large knock-in technology
• CRISPR Cas9
• MAD7

With the proven ability to knock-in 50 kb at the H11 safe harbor site, TARGATT™ technology enables insertion of multiple genes and expression cassettes.

Differentiated cell types and applications

• NK cells
• Tregs
• Microglia
• Neurons
• Cardiomyocytes
• MSCs
• CAR-NK
• CAR-macrophages
• Logic-gated CAR constructs
• Allogeneic development
• More

Advance confidently with iPSC engineering expertise and powerful technologies

When you trust your iPSC engineering to ASC, you open the door to larger possibilities.

With TARGATT™ technology, we’ve proven that we can knock-in as much as 50 kb, enabling insertion of multiple full-length genes and multi-gene expression cassettes. Design logic-gated CARs, knock-in immune evasion elements, insert large, full-length genes.

We also have extensive experience editing iPSCs with CRISPR Cas9 and MAD7 if you need additional knockouts or point mutations.

If you’d like us to engineer your iPSC line, we can still help you leverage the power of TARGATT™ technology. We’ll use MAD7 to insert a landing pad before using TARGATT™ technology to deliver your payload.

Move efficiently from engineering to functional cell types

Engineering the right iPSC line is only the first step. ASC’s long heritage in iPSC technology is the foundation for our deep expertise in differentiating engineered iPSCs into functional cell types.

With robust differentiation protocols across a range of therapeutic areas—including neural, immune, cardiovascular, and other specialized cell types—and customizable characterization assays, we drive iPSC drug discovery programs.

Because differentiation protocols are tightly integrated with our genome engineering workflows, we can rapidly translate engineered iPSC platforms into functional cells suitable for disease modeling, screening, and proof-of-concept studies—helping your team move quickly from genetic design to biological validation.

Establish GMP-grade cell banks

As promising programs move toward translation, robust cell banking becomes critical to ensure consistency, traceability, and scalability. ASC provides comprehensive research and cGMP-grade cell banking services to support the transition from discovery programs to clinical development.

Our team can generate master and working cell banks tailored to your program requirements, with customizable bank size, vial concentration, and quality testing. All banking activities are performed in our California facility with controlled environments and continuous monitoring to ensure high standards of quality and reproducibility.

By integrating genome engineering, differentiation, and cell banking within a single workflow, ASC enables teams to seamlessly advance engineered iPSC platforms from early discovery through IND-enabling development and clinical manufacturing.